SEPTERNA INC (SEPN)
Health Care · Small-molecule drug discovery and development · NASDAQ
An early-stage biotech company developing cell receptor-targeted therapeutics for inflammation, metabolism, and other diseases through its proprietary chemistry platform.
What SEPTERNA INC does
Septerna Inc is a biopharmaceutical company focused on discovering and developing small-molecule drug candidates targeting cell receptors. The company is advancing two primary pipeline programs: SEP-479 and SEP-631, with preclinical and clinical development efforts aimed at treating inflammatory, metabolic, and other disease indications. Septerna operates through a partnership with Novo Nordisk A/S to leverage its chemistry platform and expand its therapeutic reach.
Themes: ["Small-molecule drug discovery","Cell receptor therapeutics","Inflammatory disease treatment","Metabolic disorder treatment","Early-stage clinical development"]
Fundamentals
- Price$37.84 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return+221.0% as of 2026-07-09 close
- Net margin-49.9% as of 2026-07-10
- ROE-9.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+11790.1% as of 2026-07-10
- Revenue CAGR (3y)+1644.5% SEC XBRL
- Beta0.50 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial failures and inability to replicate positive preclinical results in human trials for SEP-479, SEP-631, and other candidates","Regulatory approval delays or denials for IND applications and FDA clearance of product candidates","Dependence on partnership with Novo Nordisk and risk of partnership termination or failure to achieve intended benefits"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.